GlassScriptPhysician profile
Alison Pietras
NPI 1669961629
$6,381.44
in general payments reported to CMS, 2019-2025
4 companies · $17.78 in 2025
The $17.78 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $4,365 · 2024: $1,999 · 2025: $17.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,480 · Consulting Fee: $1,735 · Travel and Lodging: $859 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $800 · Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,480.00 |
| Consulting Fee | $1,735.00 |
| Travel and Lodging | $858.68 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $800.00 |
| Food and Beverage | $507.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $6,238.66 | 2023-2024 | |
| Lilly USA, LLC | $125.00 | 2024 | Kisunla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.78 | 2025 | Xifaxan |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Pietras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.